Innate Pharma
IPHA
8 hedge funds and large institutions have $469K invested in Innate Pharma in 2024 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 2 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
0.02% less ownership
Funds ownership: 0.31% → 0.3% (-0.02%)
11% less funds holding
Funds holding: 9 → 8 (-1)
36% less capital invested
Capital invested by funds: $731K → $469K (-$262K)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$59.1K |
| 2 |
Optiver Holding
Amsterdam,
Netherlands
|
+$42.2K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$219 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ETC
Exchange Traded Concepts
Oklahoma City,
Oklahoma
|
-$67.4K |
| 2 |
Jane Street
New York
|
-$41.9K |
| 3 |
Millennium Management
New York
|
-$30.5K |
| 4 |
Morgan Stanley
New York
|
-$1.51K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Optiver Holding
Amsterdam,
Netherlands
| $169K | +$42.2K | +16,788 | +24% |
|
|
ETC
2
Exchange Traded Concepts
Oklahoma City,
Oklahoma
| $167K | -$67.4K | -26,833 | -24% |
|
|
3
Morgan Stanley
New York
| $84.4K | -$1.51K | -600 | -1% |
|
|
4
Citadel Advisors
Miami,
Florida
| $45.6K | +$59.1K | +23,527 | New |
|
5
Barclays
London,
United Kingdom
| $799 | – | – | – |
|
|
6
UBS Group
Zurich,
Switzerland
| $576 | +$219 | +87 | +41% |
|
7
RhumbLine Advisers
Boston,
Massachusetts
| $397 | – | – | – |
|
|
SPIA
8
Steward Partners Investment Advisory
New York
| $388 | – | – | – |
|
|
9
Jane Street
New York
| – | -$41.9K | -14,554 | Closed |
|
|
10
Millennium Management
New York
| – | -$30.5K | -10,579 | Closed |
|
IPHA Hedge Fund Activity: Q2 2024 in Review
8 of the 6,927 institutional investors tracked by Wall St. Rank reported a position in Innate Pharma (IPHA) for Q2 2024, worth a combined $469K — down 36% from $731K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of IPHA and 1 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 2 added.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $59.1K. The largest seller was Exchange Traded Concepts, cutting an estimated $67.4K.
- 8 institutional investors held Innate Pharma (IPHA) as of Q2 2024, down from 9 in Q1 2024.
- Funds reported $469K of Innate Pharma stock for Q2 2024, down 36% quarter-over-quarter.
- 1 fund opened new Innate Pharma positions in Q2 2024 and 2 closed out, a net change of -1 holder.
- The largest Innate Pharma buyer in Q2 2024 was Citadel Advisors, an estimated $59.1K added.
- The largest Innate Pharma seller in Q2 2024 was Exchange Traded Concepts, an estimated $67.4K sold.
Based on aggregated 13F filings for Q2 2024.